Method of higher meat production of broilers and related preparation
FIELD: medicine; veterinary science.
SUBSTANCE: method of higher meat production of broilers provides single injection for day birds of liposomal forms of preparation containing chimeric protein with water insoluble enzyme-inactive chloramphenicol acetyltransferase without 10 S-terminal aminoacids, aminoacid spacer (Sp)n, where n=1, 2, 4, 8 and somatostatin-14 with aminoacid sequence AGCFWKTFTSC, with median size of liposomes 250±50 nm. And preparation is introduced in combination with Marek's disease factor vaccine.
EFFECT: invention allows for higher effective meat production of broilers using single injection of preparation during the whole fattening period.
2 cl, 1 tbl
The invention relates to a meat poultry, and particularly to a method of increasing meat efficiency of broilers and preparation for its implementation.
Modern poultry in several ways solves the problem of maximum utilization of the genetic potential of the birds while maintaining its productive health. Accelerated growth and increased daily liveweight gain of broilers at lower economic cost per 1 kg increase in live body weight is one of the main tasks in meat poultry. For many years, were used for growth promoting antibiotics, get the bird to feed at certain concentrations. However, the advent and widespread in the late 80-ies of XX century antibiotic-resistant strains of microorganisms, with cross-resistance to antibacterial compounds used in medicine, has resulted in a dramatic reduction in the frequency and volume of use of antibiotics in poultry production. At the present stage in many countries, in particular in the States of the EEC, have banned the use of antimicrobial drugs as growth-promoting additives in feed the bird.
There are other, indirect methods of raising meat efficiency of broilers. These include the introduction of trace elements (the particular selenium), vitamins to feed the bird, the application of humic substances. All of these methods provide for multiple use of feed additives and is aimed primarily at optimizing the composition of feed mixtures for a number of controllable parameters.
The direct method of raising meat efficiency of broilers aimed at increasing concentrations of growth hormone (somatotropin) in the body of the bird. This can be achieved by using chemically synthesized somatotropin. However, the drug's high cost makes this method of increasing productivity is not always cost-effective, and the use of hormonal drugs is a negative attitude in society.
There is another method of increasing the concentration of endogenous somatotropin, by reducing the concentration in the body of his antagonist - somatostatin.
Somatostatin is a biologically active tetradecapeptide. Produced in the hypothalamus and the gastrointestinal tract of animals and birds. The sequence of somatostatin-14 markedly conservative among vertebrates. Somatostatin exerts a strong inhibitory effect on a wide range of hormones and related body functions. A broad spectrum of action of somatostatin on the factors necessary for the disposal of food, opens up great prospects for use as PE is ulator poultry. In this regard, great interest is the autoimmune reaction of the body of the bird on the introduction somatostatinergic protein, leading to a decrease in the concentration of peptide in the blood and, as a consequence, the induction of anabolic factors and the growth of birds.
Research showed that immunized drugs somatostatin animals showed increase in daily gain of body weight by 10-20%, increase in the efficiency of digestion and utilization of food by 11%. While there is an improved absorption of nutrients and slow its passage through the GI tract. Immunized with somatostatin animals and their offspring have the correct proportions and mass distribution of the body. However, the practical distribution of livestock antisomatostatin immunotherapy has not received due to the high cost of chemically synthesized somatostatin. Because of the small size of the somatostatin-14 does not allow its direct microbial synthesis using recombinant DNA technology described several ways to carry out the synthesis in the form of a chimeric protein with the specific selection of the target product, not given, however, satisfactory results. The main disadvantage of the above methods is extremely low immunogenicity obtained drugs in related and somatostatin, due to its masking of the molecule in the chimeric protein, therefore, these methods of producing chimeric proteins did not find wide practical use (R. Itakura et al., 1977 Expression in E. Coli of a chemically synthesired gene of hormone somatostatin, Science, 1986, 1056-1063; A.A. Shishkin and other Synthesis fragment somatostatin genes. Chemistry of natural compounds, 1988, No. 6, s-615).
The known method of constructing chimeric somatostatinergic proteins using amino acid spacer containing arginine and Proline and contributing to the localization of somatostatin on the surface of carrier protein and, thereby, the high immunogenicity of the drug (RU C1 No. 2031121, IPC 6 C12N 15/12, 1995).
The design consists of a water-insoluble protein carrier (fragment of bacterial chloramphenicolchloramphenicol without the 10 C-terminal amino acids), tetramer spacer and C-terminal somatostatin-14. The molecular weight of the chimeric Beja is 28 kDa. This chimeric protein is expressed by a strain of E.coli In-6519 transformed by the plasmid pC(Sp)4S. Strain deposited in Russian national collection of industrial microorganisms (VKPM). Chimeric protein with the exposed somatostatin is a water-insoluble enzyme inactive chloramphenicolchloramphenicol without 10 terminal amino acid residues, which through the spacer elements of the sequence p is soedineni sequence of somatostatin-14.
Method antisomatostatin immunization of animals with the use of this chimeric somatostatinergic protein is used in the cattle industry (EN C1 No. 2034457, IPC 6 AC 67/02, 1995).
The result of the invention consists in developing a method of raising meat efficiency of broilers by applying a liposomal form of the drug with chimeric somatostatinomas protein.
This result is achieved by way of increasing meat efficiency of broilers provides a single injection at day old birds liposomal form of the drug containing chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8 and somatostatin-14 amino acid sequence AGCFWKTFTSC in liposomal form, with a median size of liposomes 250±50 nm. The introduction of the drug carried out in conjunction with a vaccine against the causative agent of Marek's disease.
Accordingly, a drug for improving meat efficiency of broilers contains liposomal form an effective amount of a chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8 and somatostatin-14 last is the sequence of amino acids AGCFWKTFTSC, with a median size of liposomes is 250±50 nm.
The mechanism of drug action based on the temporary blocking activity of endogenous somatostatin birds and the increased concentration of endogenous growth hormone. While there is an improved absorption of nutrients and slow its passage through the gastro-intestinal tract of the bird. Once (during the whole period of fattening poultry) the introduction of the drug can significantly minimize additional technological operations personnel.
A distinctive feature of the chimeric somatostatinergic protein is its extremely low solubility in aqueous media, as well as its aggregation and subsequent occulation when attempting to obtain a homogeneous dispersion in the case of the introduction in aqueous solutions of the true protein solution in other solvents, easily miscible with water. As a consequence, may be difficult to obtain a homogeneous dispersion with a low protein concentration (1·10-3g/ml) in the aquatic environment for the introduction of living organisms with body weight is 40-50,
This purpose was developed liposomal form of the drug, in which chimeric somatostatinergic protein is located within the highly dispersed phospholipid vesicles. When this protein inside each vesicles, not to communicate with the t protein, prisoners in other phospholipid education. This factor prevents the formation of protein aggregates. It is also important that the high stability of the obtained fine liposomal system (the median size of liposomes 200 nm, the stability of more than 1 year) allows to obtain a homogeneous concentration of protein in the whole volume of the system.
The feasibility of introducing the drug in conjunction with a vaccine against the causative agent of Marek's disease is caused only by the desire to reduce the degree of injury to birds by conducting several courses of vaccination. The drug can be used alone, without vaccines against the causative agent of Marek's disease, which on the effectiveness of the drug has no effect.
The possibility of carrying out the invention is illustrated by the example of getting a drug to increase meat productivity of broiler chickens.
Obtained and purified from the impurities of the drug is protein dissolved in buffer 0.2 M Tris - HCl pH 8.0, containing 6 M guanidine hydrochloride and 2M of META. Add 50-fold molar excess of β-mercaptoethanol in the calculation of the number of S-S groups chimeric protein and the solution is quickly diluted 10-fold volume of buffer without handinhand. The resulting hybrid protein precipitate is separated by centrifugation for 15 minutes at 12000g and a temperature of 4°and freeze-dried to posleduyuschaya.
Then lyophilized preparation of protein dissolved in an aprotic solvent at the desired concentration (1·10-5-1·10-3M). The resulting solution was transferred in liposomal form by using the processing apparatus LXIV (linear stepper induction rotator) for 10-20 minutes, together with calculated amounts of phospholipids (20% alcohol solution) and distilled water. Received liposomal preparation is characterized by the following parameters: diameter of liposomes 250±50 nm; the content of phospholipids 2,5±1,0%; dry residue 5-20%. Concentration somatostatinergic protein in the final recipe of the drug is 1.35-2,70 mg/ml. Liposomal drug Packed in consumer packaging according to the normative-technical documentation.
The efficacy of the drug to increase meat productivity of broiler chickens illustrated by the following.
It was formed three analog group broiler day old 1000 animals each.
Liposomal form somatostatinergic (PRS) of the drug in a volume of 1.5 ml with a concentration of protein of 1.35-2,70 mg/ml in compliance with the rules of asepsis immediately before vaccination birds add in a bottle (200 ml) with a vaccine preparation against Marek's disease. Carefully (by shaking) mix the contents of the vial is to obtain a homogeneous concentration of the suspension in the whole volume of the vial. Inject 0.2 ml/head in accordance with the advice of immunization.
Data on the effect of liposomal forms somatostatinergic chimeric protein to meat productivity of broiler chickens (growing period 41 days) are presented in the table.
As follows from the table, a single application at day old broilers liposomal forms somatostatinergic protein at a concentration of from 2 to 4 mcg/head in conjunction with a vaccine preparation against Marek's disease leads to an increase in daily liveweight gain of a bird is in the range from 3.1% to 7.3% at the same time increase the safety of the poultry population of 1.2 to 1.6%.
|Options||Safety||Average daily gain in live weight per head|
|goals||% of control||g||% of control|
|2 mcg/1 head|
|4 mcg/1 head|
1. The way to increase meat productivity of broilers, providing a single injection at day old birds liposomal form of the drug containing chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8 and somatostatin-14 amino acid sequence AGCFWKTFTSC in liposomal form, with a median size of liposomes 250±50 nm, and the introduction of the drug carried out in conjunction with a vaccine against the causative agent of Marek's disease.
2. Drug to increase meat efficiency of broilers containing liposomal form an effective amount of a chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8 and somatostatin-14 amino acid sequence AGCFWKTFTSC, with a median size of liposomes is 250±50 nm.
SUBSTANCE: invention concerns aldehyde derivatives and conjugates of di-, oligo- or polysaccharide, of the general formula (I), methods of obtaining them, and pharmaceutical composition based on them and capable of staying in blood flow for prolonged time. , where R is -CH(CHO)CH2OH, -CH2CHO, -CH(CH2NHR1)CH2OH, -CH(CH2NHNHR1)CH2OH, -CH(CH=NNHR1)CH2OH, -CH2CH2NHR1, -CH2CH=N-NHR1, -CH2CH2NHNHR1; R1 is polypeptide or albumen; GlyO is a sialic acid bond; R3 is H; R4 is OH; n is 2 or more.
EFFECT: obtaining pharmaceutical composition based on aldehyde derivatives of sialic acid capable of staying in blood flow for prolonged time.
20 cl, 7 tbl, 22 dwg, 10 ex
FIELD: medicine; pharmacology.
SUBSTANCE: invention group refers to compositions containing hapten-carrier conjugate within arranged and repeating matrix, and method of related composition production. Offered hapten-carrier conjugate used for induction of agent-specified immune reaction in case of addiction or abuse, contains cortex particle including at least one first apposition site, where specified cortex particle is virus-like particle of RNA-phage, and at least one nicotine hapten with at least one second apposition site, where specified second apposition site is associated by at least one covalent non-peptide bond with specified first apposition site, thus forming arranged and repeating hapten-carrier conjugate. Offered conjugates and compositions under this invention can include virus-like particles connected to various haptens including hormones, toxins and agent, especially agents causing addiction, as nicotine and can be applied for induction of hapten immune reaction for therapeutic, preventive and diagnostic purposes.
EFFECT: vaccines can induce stable immune reactions for nicotine and fast reduce nicotine availability for brain absorbing.
31 cl, 6 dwg
FIELD: medicine, virology, immunology, molecular biology.
SUBSTANCE: invention involves a composition comprising a regulated and repeated matrix of antigens or antigen determinants and, in particular, matrix comprising RANKL protein, RANKL fragment or RANKL-VLP peptide. Invention relates to a composition comprising viral-like particle and at least one RANKL protein, RANKL fragment or RANKL peptide bound with its, and to a method for preparing conjugates and regulated and repeated matrices, respectively. Proposed compositions can be used for preparing vaccines used in treatment of bone diseases and as a pharmaceutical vaccine used for prophylaxis or treatment of bone diseases, and for effective induction of immune responses, in particular, humoral responses. The advantage of invention involves enhancing induction of immune responses to RANKL protein.
EFFECT: valuable biological and medicinal properties of matrices.
28 cl, 7 dwg, 20 ex
FIELD: medicine, polymers.
SUBSTANCE: invention relates to conjugates consisting of a water-soluble polymer of molecular mass from 200 to 20000 Da and representing polyethylene glycol or alkyl chain to which two molecules of synthetic peptides, not less, are bound by reactive functional group and wherein each peptide comprises amino acid sequence originating from region HR1 or HR2 of human immunodeficiency virus (HIV) gp41. Invention relates to methods for using these conjugates for delivery inhibition of to HIV target-cell by addition of indicated conjugates in the amount providing effective inhibition of cell infection with indicated virus. Also, invention relates to methods for preparing conjugates by functional adding of each molecule of synthetic peptide to polymer through reactive functional group.
EFFECT: valuable biological properties of conjugates.
27 cl, 2 dwg, 6 tbl, 6 ex
FIELD: chemical and pharmaceutical industry.
SUBSTANCE: invention relates to lyophilized pharmaceutical immunocytokine composition including immunocytokine and containing as cytokine component interleukin-2 (IL-2), sugar or aminosugar, amino acid and surfactant, wherein said composition contains: immunocytokines from 0.1 to 25 mg/ml; sugar or aminosugar 1-200 mg/ml; amino acid 1-200 mMol/l; and surfactant 0.001-1 mass %.
EFFECT: composition for parantheral administering with prolonged storage time even at increased temperatures.
13 cl, 8 ex, 4 tbl, 2 dwg
SUBSTANCE: method involves carrying out single-stage conjugate synthesis having stereospecific (affine) compound conjugated in covalent way to suspensoid carbon particles.
EFFECT: enabled direct analyte observation on solid phase surface as back spots; increased sensitivity of diagnosticum for performing immunochemical, gene-hybridizing and ligand-receptor studies and creating instrumentless rapid diagnosis test systems.
FIELD: chemical-pharmaceutical industry, proteins.
SUBSTANCE: invention concerns to cytokine-containing fused proteins showing the enhanced therapeutic index, and methods for enhancing the therapeutic index of these fused proteins. Fused proteins are able for binding with cytokine receptors of more one type expressed on cells and to bind with cells of more one type also. Except for, fused proteins possess a half-time value in blood stream of a patient as compared with that of corresponding natural cytokines.
EFFECT: improved and valuable properties of cytokines.
21 cl, 3 tbl, 11 ex
FIELD: medicine, radiation medicine.
SUBSTANCE: method involves subcutaneous administration of anti-influenza vaccine "Grippol" in the effective dose. Invention provides enhancing effectiveness of body to effect of ionizing radiation. Invention can be used for prophylaxis of radiation damage.
EFFECT: improved method of prophylaxis.
5 tbl, 2 ex
FIELD: medicine, oncology, peptides.
SUBSTANCE: invention relates to a chimeric protein used in treatment of malignant lymphomas. Invention proposes chimeric protein consisting of two peptides representing inhibitor of cyclin kinases as an active fragment p16INK4a with amino acid sequence 84-13 or 84-106 as a therapeutic agent and the second peptide VP22 with sequence 140-301 of virus herpes simplex as a transporting agent. Advantage of the invention involves the development of preparation of high effectiveness of penetration into cells and possessing cytostatic and cytotoxic effects.
EFFECT: valuable medicinal properties of chimeric protein.
1 dwg, 2 ex
FIELD: medicine, biotechnology.
SUBSTANCE: invention relates to the development of a recombinant fused protein consisting of an oncoprotein E7 VPCH 11 type with a sequence SEQ № 2 and protein of "heat shock" Hsp 70 from M. tuberculosis cells prepared by using plasmid pQE30-E711-dnaK in E. coli cells. The preparation is used against relapsing human papillovirus comprises the recombinant fused protein in the effective amount and a pharmaceutically acceptable carrier. Method for immunotherapy of relapsing larynx papillomatosis involves intracutaneous administration of indicated preparation in a patient. The advantage of invention involves the development of a novel preparation showing improved immunological indices. Proposed preparative formulations can be used in immunotherapy of relapsing larynx papillomatosis in humans.
EFFECT: valuable medicinal properties of protein, improved method for treatment.
3 cl, 6 dwg, 7 ex
SUBSTANCE: method includes measurement and value assignment of temperature felt by animals and poultry in zones of local heating, comparison of measured and set values, mode regulation of local heating by result of comparison, measurement of temperature value of air in room and assignment of its standard minimum and maximum values. There is measurement of external air temperature value and of relative humidity of external and internal air in room. Depending on changeable signal of generated temperature value of air in room costs of energy consumption on local and on general heating are calculated and cost of expenses from losses of animal husbandry products. Cost of expenses for forages for a livestock is calculated. Costs of energy consumption on general and local heating are calculated. Signals of natural combustible gas resources and drinking water consumption are measured; set signals are formed about values of specific prices of enterprise on natural combustible gas and drinking water. A temperature mode of general heating of industrial rooms with local heating is corrected. The device contains sensors of felt temperature in a zone of local heating, temperatures of internal air in room, set-point devices for a livestock age, technologically admissible minimum and maximum temperatures of air in room, set value of felt temperature, standard temperature of air, temperature regulators of local and general heating, local heaters and heat exchangers. The device contains temperature sensors of external air, relative humidity of internal and external air, set-point device of interrogation time, signal of generated temperature value of air in room, constants, the first, the second and the third computing blocks, an adder, a control block, a differentiating amplifier. Into the device the fourth computing block united together with the first, the second and the third computing blocks in a block of calculation, set-point devices of specific prices for thermal energy, for electric energy, for enterprise production, for forages, an interface and communication block, a block of the computer hardware and software focused network means, a peripheral block of computer network are entered. Flow sensors of gas and water are in addition entered into the device accordingly, also set-point devices of signals about values of the enterprise specific prices accordingly on natural combustible gas and drinking water, signal formers of conformity to data of local, regional and international Internet info-communication computer networks about specific prices for gas and water, the first and the second comparison schemes, the first and the second multiplication schemes.
EFFECT: minimisation of operational expenses for general and local heating.
2 cl, 2 dwg
SUBSTANCE: method includes an irradiation of eggs before a laying on incubation by electromagnetic radiation. Incubatory eggs are irradiated within 0.1 to 30 seconds with a dose 50 to 3000 mJ/m by a source of not polarised, not coherent polychromatic radiation within 250-310 nanometres.
EFFECT: increase of poultry young hatchability.
3 tbl, 3 ex
SUBSTANCE: method includes the processing of eggs and chickens by low-intensity electromagnetic radiation. First of all the incubation eggs are exposed to radiation by EMP EHF before putting into the incubator with the power density on the egg's surface of 0.3 mW/cm2 during 3-6 minutes. Then under the same conditions the day-old chickens are exposed to radiation before the first vaccination. Then during the technological growth cycle subsequent periodic radiation exposure of chicken is carried out in the same mode every 6 days but not later than 72 hours before the regular vaccination.
EFFECT: immunity of poultry increases.
2 cl, 3 tbl, 2 ex
FIELD: veterinary science, poultry science.
SUBSTANCE: the present innovation deals with pre-incubation treatment of hen embryos with the light of fluorescent lamp DNESG-500 at wave length of 630-650 nm, average dosage at egg surface being 23.1 erg at exposure of 17 sec, with He-Ne laser LHN-104 at wave length of 632.8 nm, power density of optic flow at egg surface being 50 mW/sq. cm·sec at exposure of 3 sec, with mercury-quartz lamp DRT-400 at wave length of 400/185 nm, average dosage at egg surface being 20 merg/h at exposure of 3 min. Moreover, such treatment should be fulfilled before laying for incubation on the 6th, 12th, 18th d of incubation and in daily chickens 4-fold at 5-min-long interval. Then comes disinfection from all the sides with two bactericidal lamps BUV-15 at wave length of 254/800 nm, nominal power at egg surface being 15 W at exposure per 5 sec and with three bactericidal lamps BUV-30 at wave length of 254/800 nm, nominal power at egg surface being 30 W at exposure of 17 sec. Incubated broiler chickens should be immunized with the vaccine of "Bor-74 BGNKI" strain. The innovation enables to increase specific resistance to Newcastle disease in poultry.
EFFECT: higher efficiency.
FIELD: veterinary science.
SUBSTANCE: the present innovation deals with heating hens' embryos with light of fluorescent lamp DNESG-500, wave length being 630-650 nm, average dosage at eggs surface being 23.1 erg at exposure of 5 min, irradiation with He-Ne laser LHN-104, wave length being 632.8 nm, power density of optic flow at eggs surface being 50 mW/sq. cm, with mercury-quartz lamp DRT-400, wave length being 400/185 nm, average dosage at eggs surface being 20 mErg/h out of "Bor-74 VGNKI" strain. Light treatment of embryos in the same mode and poultry immunization should be combined with eggs disinfection from all sides with two bactericidal lamps BUV-15, wave length being 254/800 nm, nominal power at eggs surface of 15 W and three bactericidal lamps BUV-30, wave length being 254/800 nm, nominal power of 30 W at exposures per 3 min. And poultry light treatment in the same mode should be carried out before incubation on the 6th, 12th, 18th d of embryos development and in incubated day-long chickens. The innovation prolongs survival rate in broilers grown under industrial conditions being unfavorable on Newcastle disease.
EFFECT: higher efficiency.
FIELD: poultry science.
SUBSTANCE: the present innovation deals with pre-incubation treatment of hen embryos with the light of fluorescent lamp DNESG-500 at wave length being about 630-650 nm, at average dosage at egg surface being 23.1 erg in exposure of 5 min, with the light of He-Ne laser LHN-104, at wave length being 632.8 nm, power density at egg surface being 50 mW/sq. cm, with the light of mercury-quartz lamp DRT-400 at wave length being 400/185 nm, average dosage at egg surface being 20 merg/h in exposures of 3 min and due to immunization with vaccine out of "Bor-74 VGNKI" strain. Light treatment of embryos and immunization in broiler chickens should be combined with egg disinfection from all sides with two bactericidal lamps BUV-15 at wave length being 254/800 nm, nominal power at egg surface being 15 W and with three bactericidal lamps BUV-30 at wave length being 254/800 nm, nominal power at egg surface being 30 W in exposures of 3 min. The innovation enables to increase specific resistance to Newcastle disease in poultry.
EFFECT: higher efficiency of prophylaxis.
5 dwg, 2 tbl
SUBSTANCE: method involves providing double processing of eggs; 3-4 hours before incubation, applying 0.005%-aerosol solution of preparation "Rybav" onto egg surfaces by means of sprayer; before hatching, applying 0.25%-solution of said preparation. Prior to applying said preparation, it is dissolved in distilled water at temperature of 8-22 C.
EFFECT: increased hatchability and reduced losses of young chicken.
3 tbl, 3 ex
SUBSTANCE: method involves providing triple treatment of eggs with glycin solution and succinic acid solution; spraying glycin solution and succinic acid solution onto egg shell surface; treating eggs before incubation and on 7th day of incubation with glycin solution; treating eggs on 19th day of incubation with succinic acid solution; using glycin in 0.5-1%-concentration and succinic acid in 0.3-0.5%-concentration; spraying said solutions onto 120-150 eggs during 6-12 hours before incubation at air temperature of 20-22 C within house.
EFFECT: increased efficiency of method owing to stimulating of embryogenesis processes, and increased yield of standard young farm birds.
FIELD: agricultural engineering.
SUBSTANCE: method involves treating eggs by providing vacuum sucking of preliminarily heated eggs in incubator at temperature of 37.6 C during 5-6 hours; providing aerosol treatment of incubation eggs with degassed water in disinfection chamber at temperature of 18-22 C with dose of 1.5-2 ml/m3, followed by exposing within cloud during at least 30 min.
EFFECT: increased capacity of egg hatching, reduced withdrawal of young animals, increased content of lysozyn and bacterial activity in chicken blood whey.
2 tbl, 2 ex
FIELD: pre-incubation treatment of meat-type chicken eggs.
SUBSTANCE: method involves treating eggs with biologically active compositions, with organosilicon substances such as cresacin and meval being used as biologically active compositions. Said compositions are applied in the form of mixture of their solutions onto eggshell 6-12 hours before incubation.
EFFECT: increased chicken yield and intensified growth of chickens.
3 tbl, 3 ex
FIELD: poultry science.
SUBSTANCE: one should irradiate eggs before incubation with the light of He-Ne laser LHN-104, wave length being 632.8 nm, power density at eggs surface being 50 mW/sq.cm/sec, with red light of fluorescent lamp DNESG-500, wave length being 630-650 nm, power at eggs surface being 23.1 erg and with ultraviolet from DRT-400 lamp at wave length being 185-400 nm, average dosage at eggs surface being 20 merg in 3-min-long exposures.
EFFECT: higher resistance to pullorosis in poultry.
4 dwg, 4 tbl